Personalized cancer vaccine cuts skin cancer recurrence by 42%

Trial results show a personalized therapeutic vaccine for skin cancer (melanoma) reduced the risk of the disease returning by 42%. The results, from Moderna and Merck, provide scientific support for the approach of treating with vaccines, although the therapy remains experimental.

AI-written summary of 2 sources; every verified point is backed by a verbatim quote. How Iyan works

• The results, from Moderna and Merck, add scientific support for the approach of treating with vaccines.

  «results from Moderna and Merck add scientific support for a vaccine-based approach to treating the cancer»

  TIME
• The vaccine uses the same messenger RNA technology that helped end the COVID-19 pandemic.

  «The skin cancer vaccine is based on mRNA technology that helped end the coronavirus pandemic.»

  The Washington Post
• Sources described the therapy as still experimental and not yet approved as an available treatment.

  «The treatment is still experimental, but results from Moderna and Merck»

  TIME

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms